Drug Pipeline Database & Screener

Over 2000 drug entries from about 550 biotech companies in Phase 2, 3 or NDA development.

Company SCREENER also available to filter through financial and clinical data. Financial filters include market cap, short ratio, price to book and relative volume, while you can also run a filter according to the development stage of the drug (e.g. Phase 2, PDUFA date).

NASDAQ and NYSE stocks only are shown. OTC stocks are not covered on BioPharmCatalyst.

Subscribe HERE to ensure you receive your weekly free copy of the BioPharmCatalyst Biotech Watchlist and/or our daily option of Biotech Price Movers and Pipeline Database updates.

Financial data are delayed 15-25 minutes.

Showing companies

Screener

Sort

Company Price Change Market Cap Outstanding Shares Short Ratio Updated

Stage

Any... Phase 1a Phase 1 Phase 1b Phase 1/2 Phase 2a Phase 2 Phase 2b Phase 2/3 Phase 3 NDA Filing sNDA Filing BLA Filing PDUFA PDUFA priority review Approved CRL

Indication

Any... 22q11.2 Deletion Syndrome AADC deficiency Abdominal symptom claims (ASC) Achalasia Achondroplasia Achromatopsia Acid sphingomyelinase deficiency (ASMD) Acinetobacter baumannii infections Acne Acquired thrombotic thrombocytopenic purpura (aTTP) Acromegaly Actinic keratosis Acute bacterial skin and skin structure infections (ABSSSI) Acute Coronary Syndrome Acute hepatic porphyrias Acute lymphoblastic leukemia (ALL) Acute myeloid leukemia (AML) Acute myocardial infarction (AMI) Acute otitis externa Acute Promyelocytic Leukemia acute pyelonephritis Acute Respiratory Distress Syndrome Acute-on-Chronic Liver Failure (ACLF) Adenosine deaminase severe combined immunodeficiency (ADA-SCID) Adenovirus ADHD Adrenoleukodystrophy (ALD) Adult Growth Hormone Deficiency (AGHD) Age-related macular degeneration (AMD) Agitation Alagille Syndrome (ALGS) Alcohol Use Disorder Alcohol-induced liver decompensation (AILD) Alcoholic Hepatitis Alcoholic steatohepatitis (ASH) Allogeneic hematopoietic cell transplantation (HCT) Alopecia areata Alpha-1 Antitrypsin deficiency (AATD) Alport Syndrome Alstrom Syndrome Alzheimer’s disease Ammonia Amyloidosis Amyotrophic Lateral Sclerosis (ALS) Anal cancer Anal fissures Anaphylaxis ANCA-associated vasculitis (AAV) Androgenetic alopecia (AGA) Androgenic Alopecia Anemia Angelman syndrome Angina Angiosarcoma Animal related Ankylosing spondylitis Anthrax Arginase I deficiency Asthma Atopic dermatitis Atopic keratoconjunctivitis Atrial fibrillation (AF) ATTR (transthyretin amyloidosis) atypical Hemolytic Uremic Syndrome (aHUS) Autism Autism Spectrum Disorder (ASD) Auto-immune Hemolytic Anemia (AIHA) Autoimmune pulmonary alveolar proteinosis (PAP) Autosomal Dominant Hypocalcemia Type 1 (ADH1) autosomal dominant retinitis pigmentosa (adRP) Autosomal Recessive Congenital Ichthyosis Autosomal Recessive Stargardt Disease Axial Spondyloarthritis Axillary hyperhidrosis B-Cell Lymphoma Back pain Bacteremia Bardet-Biedl Syndrome Barth Basal cell carcinoma Batten Disease Behcet's Disease Benign Prostatic Hyperplasia (BPH) Beta-Thalassemia Biliary atresia Biliary Tract Cancer Biosimilar Bipolar depression Bladder cancer Bladder pain syndrome/interstitial cystitis (BPS/IC) Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Bleeding Blepharoptosis Blindness Bowel related Brain cancer Brain injury Branch retinal vein occlusion (BRVO) Breast cancer Bronchiectasis Bulimia Bullous Pemphigoid Bunionectomy C. difficile Infection C3 glomerulopathy (C3G) Cachexia Candida Auris Candidemia Carcinoid Syndrome Carcinoma In-Situ (CIS) Cardiomyopathy Cardiovascular disease Cartilage/Knee Catecholamine-resistant hypotension (CRH) CDKL5 disorder Celiac disease Celluite Cervical cancer Cervical dysplasia Cervical dystonia Cervical intraepithelial neoplasia (CIN) Charcot-Marie-Tooth disease (CMT) Chemotherapy induced nausea and vomiting (CINV) Chemotherapy-induced neutropenia (CIN) Chikungunya vaccine Chikungunya Virus Infection Cholangiocarcinoma Choroideremia Chronic cough Chronic Dysphonia Chronic idiopathic constipation (CIC) Chronic inflammatory demyelinating polyneuropathy Chronic Kidney Disease-Associated Pruritus Chronic Lymphocytic Leukemia (CLL) Chronic myelogenous leukemia Chronic myeloid leukemia Chronic myelomonocytic leukemia (CMML) Chronic obstructive pulmonary disease (COPD) Chronic Prostatitis Chronic spontaneous urticaria Chronic Urticaria Clear Cell Renal Cell Carcinoma Cocaine related Cold agglutinin disease Colon cancer Colorectal cancer Community-acquired bacterial pneumonia (CABP) Complement-dependent Nephropathies (CDN) Complex regional pain syndrome (CRPS) Complicated intra-abdominal infections (cIAI) Complicated urinary tract infections (cUTI) Condyloma Congenital Adrenal Hyperplasia (CAH) Congenital hyperinsulinism Congenital Myasthenic Syndromes (CMS) Conjunctivitis Connective tissue growth factor (CTGF) Constipation Contact lens Contraception Contrast-induced Nephropathy Coronary artery disease (CAD) Coronary microvascular dysfunction (CMD) Cow’s milk protein allergy (CMPA) Crigler-Najjar Critical limb ischemia (CLI) Crohn’s Disease Cushings syndrome Cutaneous fibrosis Cutaneous squamous cell carcinoma Cutaneous T-cell lymphoma (CTCL) Cystic fibrosis Cystinosis Cystinuria Cytomegalovirus (CMV) Danon disease Degenerative cervical myelopathy (DCM) Delayed sleep phase disorder (DSPD) Dementia Dengue Depression Dermal scarring Dermatomyositis Desmoid tumors Developmental and Epileptic Encephalopathies (DEE) Diabetes Diabetic cardiomyopathy (DbCM) Diabetic Foot Ulcers Diabetic macular edema (DME) Diabetic nephropathy Diabetic neuropathy Diabetic Orthostatic Hypotension Diabetic Retinopathy Diarrhea Diffuse Intrinsic Pontine Glioma (DIPG) Diffuse Large B-Cell Lymphoma (DLBCL) Dilated cardiomyopathy (DCM) Dravet Syndrome Dry eye disease Duchenne Muscular Dystrophy Ductal Carcinoma in Situ (DCIS) Dyslipidemia Ebola Eczema Egg Allergy End Stage Renal Disease on Dialysis Endometrial cancer Endometriosis Eosinophilic esophagitis Eosinophilic Gastritis Eosinophilic Granulomatosis with Polyangiitis (EGPA) Epidermolysis Bullosa Epilepsy Epithelioid Sarcoma Epstein-Barr virus (EBV-PTLD) Erectile dysfunction Erosive esophagitis Erythropoietic protoporphyria (EPP) Esophageal cancer Esophagitis Esophagogastric adenocarcinoma Essential hypertension Essential thrombocythemia Essential tremor Ewing sarcoma Exocrine pancreatic insufficiency (EPI) Fabry disease Facioscapulohumeral muscular dystrophy (FSHD) Factor Xa Familial Adenomatous Polyposis (FAP) Familial amyloid polyneuropathy (FAP) Familial amyloidotic cardiomyopathy (FAC) Familial chylomicronemia syndrome (FCS) Familial partial lipodystrophy (FPL) Fanconi Anemia (FA) Fascioliasis Fatty Acid Oxidation Disorders (FAOD) Female Sexual Arousal Disorder (FSAD) Female sexual dysfunction (FSD) Fibrodysplasia ossificans progressiva (FOP) Fibromyalgia Focal segmental glomerulosclerosis (FSGS) Follicular Lymphoma Forehead lines Fragile X syndrome Frailty Friedreich's Ataxia (FA) Friedreich’s ataxia (FA) Frozen Shoulder syndrome Galactosemia Gastric cancer Gastroenteritis Gastroesophageal reflux disease (GERD) Gastrointestinal stromal tumors (GIST) Gastroparesis Gaucher disease Generalized anxiety disorder (GAD) Generalized pustular psoriasis Genital warts Geographic atrophy (GA) Gestational Trophoblastic Neoplasia (GTN) Giant cell arteritis (GCA) Glabellar lines Glaucoma Glioblastoma Multiforme (GBM) Glioma Glomerulopathies Glucocorticoid-induced osteoporosis (GIOP) Glut1 DS Glycogen Storage Disease GM1 gangliosidosis GM2 gangliosidosis GNE Myopathy Gonorrhea Gorlin syndrome Gout Graft versus host disease (GvHD) Granulomatosis with polyangiitis (GPA) Growth hormone deficiency GSD1 Gynecomastia H. pylori Hair-related Head and Neck Cancer Headache Hearing loss Heart failure Heat stroke Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) Hemochromatosis Hemophilia Hemophilia A Hemophilia B Hemorrhoids Hemostasis Hepatic Cirrhosis Hepatic encephalopathy Hepatic porphyrias Hepatitis B Hepatitis C (HCV) Hepatitis delta virus (HDV) Hepatocellular carcinoma (HCC) Hepatorenal syndrome (HRS) Hereditary Angioedema (HAE) Hernia Herpes Heterozygous Familial Hypercholesterolemia (HeFH) Hidradenitis Suppurativa High Triglycerides Hip-related HIV Hodgkin lymphoma Homocystinuria Homozygous familial hypercholesterolemia (HoFH) Hospital-Acquired Bacterial Pneumonia Hot flashes Human lipomas Human Papilloma Virus (HPV) Huntingtons disease Hutchinson-Gilford Progeria Syndrome (HGPS) Hyperammonemia Hypercholesterolemia Hypereosinophilic syndrome (HES) Hyperkalemia Hyperlipidemias Hyperoxaluria Hyperphosphatemia Hyperprolactinemia Hypertension Hypertriglyceridaemia Hypertriglyceridemia Hypertrophic cardiomyopathy (HCM) Hyperuricemia Hypoactive sexual desire disorder (HSDD) Hypoglycemia Hypogonadism Hypoparathyroidism Hypotension Hypothyroidism Idiopathic Hypersomnia Idiopathic Polypoidal Choroidal Vasculopathy Idiopathic pulmonary fibrosis (IPF) IgA nephropathy IgG4-Related Disease Immune Thrombocytopenic Purpura (ITP) Immune-mediated necrotizing myopathy (IMNM) Incisional complications Indolent Systemic Mastocytosis Infantile spasms (IS) Infections - various Inflammatory bowel disease (IBD) Influenza Inherited Metabolic Disorders (IMD) Insomnia Intermittent claudication (IC) Intestinal Failure Associated Liver Disease (IFALD) Invasive aspergillosis Invasive candidiasis Invasive Pulmonary Aspergillosis (IPA) Irritable bowel syndrome (IBS) IVF Jaundice Jet Lag Disorder Juvenile idiopathic arthritis (JIA) Kaposi’s sarcoma Keloids Kidney disease Knee arthroplasty Lactose intolerance Lambert-Easton Myasthenic Syndrome (LEMS) Lassa virus Leber's Congenital Amaurosis (LCA) Leber’s hereditary optic neuropathy (LHON) Leiomyosarcoma (LMS) Lennox-Gastaut syndrome Leukemia Leukocyte Adhesion Deficiency-I (LAD-I) Levodopa-Induced Dyskinesia Lipodystrophy Liposarcoma Liver cancer Liver Cirrhosis Liver disease Liver fibrosis Low Cardiac Output Syndrome Lung cancer Lung transplant rejection Lupus Lymphatic Malformations (LMs) Lymphedema Lymphoma Macular Edema Malaria Malignant hyperthermia Malignant pleural disease Mantle cell lymphoma (MCL) Marginal zone lymphoma Medullary thyroid cancer Melanoma Membranous nephropathy Ménière's disease Meningitis Menkes disease Merkel cell carcinoma MERS virus (Middle East Respiratory Syndrome) Mesothelioma Metachromatic leukodystrophy (MLD) Methylmalonic Acidemia (MMA) Microsatellite Instability-High Cancer Microscopic polyangiitis (MPA) Migraine Mitochondrial Myopathy Mmyxoid/round cell liposarcoma (MRCLS) Molluscum Contagiosum Molybdenum cofactor deficiency (MoCD) Motion sickness MPS 7 MPS I MPS II MPS III MPS IIIA MPS IIIB MPS IVA Mucocutaneous candidiasis Multiple myeloma Multiple Osteochondroma (MO) Multiple Sclerosis (MS) Multiple system atrophy (MSA) Myasthenia Gravis (MG) Mycosis Fungoides Mydriasis Myelodysplastic syndromes (MDS) Myelofibrosis Myocardial ischemia Myopia Narcolepsy Nasal polyps Nasopharyngeal cancer Nasopharyngeal carcinoma (NPC) Neuroblastoma Neuroendocrine tumors Neurofibromas Neurogenic Orthostatic Hypotension (nOH) Neuromyelitis Optica Spectrum Disorder (NMOSD) Neuropathic pain Neutropenia Nicotine Addiction Niemann-Pick Disease Non-cystic fibrosis bronchiectasis (non-CF BE) Non-Hodgkin Lymphoma (NHL) Non-infectious uveitis Non-small cell lung cancer (NSCLC) Nonalcoholic fatty liver disease (NAFLD) Nonalcoholic steatohepatitis (NASH) Nonproliferative Diabetic Retinopathy Nontuberculous mycobacteria (NTM) Norovirus Obesity Obsessive compulsive disorder (OCD) Obstructive Sleep Apnea (OSA) Ocular Inflammation Oculopharyngeal Muscular Dystrophy Oncology Opioid dependence Opioid overdose Opioid-induced constipation (OIC) Oral Mucositis Ornithine Transcarbamylase (OTC) Deficiency Osteoarthritis Osteogenesis Imperfecta Osteoporosis Other Otitis media Ovarian cancer Overactive Bladder (OAB) Overt hepatic encephalopathy Pain Painful Lumbosacral Radiculopathy (PLSR) Palmoplantar keratoderma (PPK) Pancreatic cancer Papulopustular Rosacea Parkinson’s disease Paroxysmal Nocturnal Hemoglobinuria (PNH) Paroxysmal supraventricular tachycardia (PSVT) Peanut Allergy Pemphigus vulgaris (PV) Pericarditis Peripheral artery disease Peripheral Neuropathic Pain (PNP) Phenylketonuria (PKU) Pheochromocytoma Phosphoglucomutase 1 (PGM1) deficiency Pigmented Villonodular Synovitis (PVNS) PKAN Plantar fasciitis Plaque psoriasis Plasma Plasminogen Deficiency Platelets Pneumococcal Disease Pneumonia Polycystic ovary syndrome (PCOS) Polycythemia Vera Pompe Disease Portal Hypertension Post-Bariatric Hypoglycemia (PBH) Post-herpetic neuralgia (PHN) Post-transplant lymphoproliferative disorder Post-traumatic stress disorder (PTSD) Posterior Uveitis Postpartum depression (PPD) Prader-Willi Syndrome (PWS) Pre-term labor Preeclampsia Presbyopia Primary axillary hyperhidrosis Primary biliary cholangitis (PBC) Primary hyperoxaluria (PH) Primary Immune Deficiency Disease (PIDD) Primary immunodeficiency (PI) Primary ovarian insufficiency (POI) Primary palmar hyperhidrosis Primary sclerosing cholangitis (PSC) Progeria Progressive familial intrahepatic cholestasis (PFIC) Progressive keratoconus Progressive supranuclear palsy (PSP) Proliferative vitreoretinopathy (PVR) Prophylaxis Prostate cancer Proteus Syndrome Prurigo nodularis Pruritus Pseudomonas aeruginosa Psoriasis Psoriatic arthritis Psychosis Pulmonary arterial hypertension (PAH) Pulmonary Hypertension Pulmonary sarcoidosis Pulmonary tuberculosis Pyoderma Gangraenosum (PG) Pyoderma Gangrenosum Pyruvate kinase deficiency Rare Bile Acid Synthesis Disorders Recurrent respiratory papillomatosis Renal cancer Renal cell cancer (RCC) Respiratory syncytial virus (RSV) Respiratory Tract Infections Retinal diseases Rett syndrome Rheumatoid Arthritis Richter's Transformation Rosacea RPE65-Deficiency S. aureus Sanfilippo syndrome Sarcomas Schizophrenia Sciatica Scleroderma Seborrheic keratosis (SK) Secondary hyperparathyroidism (SHPT) Secondary hypogonadism Seizures Severe aplastic anemia (SAA) Severe burns Severe Congenital Neutropenia (SCN) Sexual health (female) Sexual health (male) Sezary syndrome Shingles Short bowel syndrome Sialorrhea Sickle disease Sinus related Sinusitis Sjögren-Larsson Syndrome (SLS) Small cell lung cancer (SCLC) Small Fibre Neuropathy Small lymphocytic lymphoma (SLL) Smallpox Smith-Magenis Syndrome Smoking cessation Social Anxiety Disorder (SAD) Soild tumors Solid tumors Spasticity Spinal muscular atrophy (SMA) Spinal muscular atrophy (SMA) Type 1 Spinal muscular atrophy (SMA) Type 2 Spinal muscular atrophy (SMA) Type 3 Spinal-related Spinocerebellar Ataxia sporadic Inclusion Body Myositis (sIBM) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Squamous cell lung cancer SRSE Staphylococcus aureus Status Epilepticus Stress related Stress urinary incontinence (SUI) Stroke Systemic mastocytosis (SM) Systemic Sclerosis T-cell lymphoma Tardive dyskinesia Testosterone related Thrombocytopenia Thrombotic microangiopathy (TMA) Thyroid cancer Thyroid Eye Disease (TED) Tinnitus Tourette syndrome Transfusion-dependent thalassemia (TDT) Transplant Transthyretin cardiomyopathy Trigeminal Neuralgia Tuberous Sclerosis Complex Tumor-induced osteomalacia (TIO) Type 1 diabetes Type 2 diabetes Ulcerative Colitis Urea Cycle Disorder Urinary tract infections Urothelial cancer Usher Syndrome Uterine Fibroids Vascular Ehlers-Danlos Syndrome Vasculitis Vasomotor symptoms (VMS) Veno-occlusive Disease (VOD) Venous Leg Ulcers Venous Thromboembolism (VTE) Vertigo Vitiligo Vulvovaginal candidiasis (VVC) Waldenström’s macroglobulinemia Walnut Allergy Warm autoimmune hemolytic anemia (WAIHA) Warts Wet age-related macular degeneration (AMD) WHIM syndrome Wilson disease Wiskott-Aldrich Syndrome (WAS) Women's health (pain/contraception) Wounds Wrinkles X-linked adrenoleukodystrophy X-linked chronic granulomatous disease (X-CGD) X-Linked Hypophosphatemia (XLH) X-Linked Myotubular Myopathy X-linked Retinitis Pigmentosa (XLRP) X-linked retinoschisis (XLRS) X-linked Severe Combined Immunodeficiency (XSCID) Xerostomia Zika

Market Cap

Any Mega ($200bln and more) Large ($10bln to $200bln) Mid ($2bln to $10bln) Small ($300mln to $2bln) Micro ($50mln to $300mln) Nano (under $50mln) +Large (over $10bln) +Mid (over $2bln) +Small (over $300mln) +Micro (over $50mln) -Large (under $200bln) -Mid (under $10bln) -Small (under $2bln) -Micro (under $300mln)

Price

Any Under $1 Under $2 Under $3 Under $4 Under $5 Under $7 Under $10 Under $15 Under $20 Under $30 Under $40 Under $50 Over $1 Over $2 Over $3 Over $4 Over $5 Over $7 Over $10 Over $15 Over $20 Over $30 Over $40 Over $50 Over $60 Over $70 Over $80 Over $90 Over $100 $1 to $5 $1 to $10 $1 to $20 $5 to $10 $5 to $20 $5 to $50 $10 to $20 $10 to $50 $20 to $50 $50 to $100

Short ratio

Any Low (<5 days) High (>20 days) Under 5 days Under 10 days Under 15 days Under 20 days Under 25 days Under 30 days Over 5 days Over 10 days Over 15 days Over 20 days Over 25 days Over 30 days

Relative Volume

Any Over 10 Over 5 Over 3 Over 2 Over 1.5 Over 1 Over 0.75 Over 0.5 Over 0.25 Under 2 Under 1.5 Under 1 Under 0.75 Under 0.5 Under 0.25 Under 0.1

Price to book

Any Low (<3) High (>50) Under 1 Under 2 Under 3 Under 4 Under 5 Under 6 Under 7 Under 8 Under 9 Under 10 Over 1 Over 2 Over 3 Over 4 Over 5 Over 6 Over 7 Over 8 Over 9 Over 10 Over 20 Over 30 Over 40 Over 50

Apply Filters Reset Filters

Company

Price

Change

No of Shares

Market Cap

Short Ratio

Volume

Avg Daily Volume

Relative Volume

Price to Book

Open

Prev Close

EST EPCD

Updated

ABBV AbbVie Inc.

$83.65

-0.12  -0.14%

1.5 billion

$123.7 billion

10.64

3.2 million

7.9 million

0.4

-$15.04

$83.80

$83.77

01/29/2020

Tap to view 36 drug drugs

Drug	Indication	Stage	News
Depatuxizumab mafodotin ABT-414	Glioblastoma (rGBM)	Phase 3	Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.
Veliparib	Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)	Phase 3	Phase 3 trial did not meet primary endpoints - April 19, 2017.
Ibrutinib	Relapsed or refractory MCL mantle cell lymphoma	Approved	Approved November 13, 2013.
Imbruvica	Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy	Approved	Approved February 12, 2014.
Imbruvica	Deletion 17p	Approved	Approved July 19, 2014.
VIEKIRA PAK	HCV - genotype 1	Approved	Approved December 19, 2014.
IMBRUVICA	Waldenström’s Macroglobulinemia	Approved	Approved January 29, 2015 - PCYC
ABBV-8E12	Alzheimer's disease	Phase 2	Phase 2 initiation announced January 25, 2017.
Venclexta (MURANO)	Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)	Approved	Approval announced June 11, 2018.
Venetoclax - CANOVA	Relapsed or refractory multiple myeloma	Phase 3	Phase 3 data due in 2021.
Risankizumab	Psoriasis	Approved	FDA approval announced April 23, 2019.
Imbruvica	Second-line Chronic graft-versus-host disease (GVHD)	Approved	Approval announced August 2, 2017.
ABT-494	Psoriatic Arthritis	Phase 3	Phase 3 trial to commenced 2017.
Rova-T (TRINITY)	Third-line Small Cell Lung Cancer	Phase 2	Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.
Upadacitinib	Atopic Dermatitis	Phase 3	Phase 3 trial met primary and secondary endpoints - October 31, 2019.
Imbruvica	Marginal zone lymphoma	Approved	sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.
Glecaprevir/Pibrentasvir (G/P)	Hepatitis C virus (HCV)	Approved	Approval announced August 3, 2017.
Elagolix	Uterine Fibroids	NDA Filing	NDA filing announced August 5, 2019.
Elagolix	Endometriosis	Approved	FDA approval announced July 24, 2018.
ABT-494 upadacitinib	Rheumatoid arthritis	Approved	FDA Approval announced August 16, 2019.
Rova-T (TAHOE)	Second-line Small Cell Lung Cancer	Phase 3	Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.
Rova-T (MERU)	First-line Small Cell Lung Cancer	Phase 3	Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.
Imbruvica and Gazyva - iLLUMINATE	Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)	Approved	FDA approval announced January 28, 2019.
IMBRUVICA (ibrutinib)	Waldenström’s Macroglobulinemia	Approved	FDA approval announced August 27, 2018.
IMBRUVICA (ibrutinib)	Diffuse large B-cell lymphoma (DLBCL)	Phase 3	Phase 3 trial did not meet primary endpoint - noted July 11, 2018.
Venclexta	First line unfit AML	Approved	FDA approval announced November 21, 2018.
Upadacitinib - U-ACHIEVE	Ulcerative colitis	Phase 2/3	Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.
Venetoclax and obinutuzumab	Chronic Lymphocytic Leukemia	Phase 3	FDA approval announced May 15, 2019.
Ibrutinib (Imbruvica)	Pancreatic cancer	Phase 3	Phase 3 primary endpoint not met (PFS/OS).
Venclexta plus Gazyva	Chronic lymphocytic leukemia (CLL)	Phase 3	Phase 3 data presented at ASCO June 4, 2019. HR 0.35. CRR 49.5%. ORR 84.7% vs. 71.3%.
Venclexta BELLINI	Multiple myeloma	Phase 3	Phase 3 primary endpoint met.
Venetoclax and obinutuzumab	Chronic lymphocytic leukemia	sNDA Filing	sNDA filing announced June 4, 2019.
Veliparib	Ovarian cancer	Phase 3	Phase 3 presentation at ESMO 28 September 2019.
Risankizumab ( LIMMITLESS )	Psoriasis	Phase 3	Phase 3 data presented at EADV October 10, 2019.
IMBRUVICA (ibrutinib) and rituximab	Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).	sNDA Filing	sNDA filing announced November 8, 2019.
Risankizumab vs secukinumab	Plaque psoriasis	Phase 3	Phase 3 trial met primary endpoint - January 14, 2020.

ABEO Abeona Therapeutics Inc.

$2.45

-0.01  -0.41%

83.5 million

$204.7 million

526.4 thousand

1.7 million

0.31

$2.13

$2.48

$2.46

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ABO-101	Sanfilippo syndrome type B (MPS IIIB)	Phase 1/2	Phase 1/2 trial ongoing.
EB-101	Recessive dystrophic epidermolysis bullosa (RDEB)	Phase 3	Phase 3 trial initiation announced January 13, 2020.
ABO-102	Sanfilippo syndrome type A (MPS IIIA)	Phase 1/2	Phase 1/2 presentation at ESGCT October 25, 2019.
ABO-202	CLN1 disease (Infantile Batten disease)	Phase 1/2	Phase 1/2 trial planned. Timing to be announced later in 2019.

ABIO ARCA biopharma Inc.

$5.62

+0.07  +1.23%

1.6 million

$9 million

3.2 thousand

48.1 thousand

0.07

$1.02

$5.54

$5.55

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Gencaro	Chronic Heart Failure	Phase 3	Phase 3 trial to be initiated 1Q 2020 subject to financing. Interim data 4Q 2021; top-line data: 3Q 2022.

ABUS Arbutus Biopharma Corporation

$2.82

+0.06  +2.17%

63.3 million

$178.4 million

194.3 thousand

598.4 thousand

0.32

-$3.17

$2.74

$2.76

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
ARB-1467, tenofovir, and pegylated interferon	Hepatitis B (HBV)	Phase 2	Phase 2 trial ongoing but no plans to continue further development.
AB-452	Hepatitis B	Phase 1	Decision regarding clinical development due early 2020.
AB-506	Hepatitis B (HBV)	Phase 1	Development to be discontinued - noted October 3, 2019.
AB-729	Hepatitis B (HBV)	Phase 1	Phase 1a/b data due late-1Q 2020.

ACAD ACADIA Pharmaceuticals Inc.

$40.12

-1.43  -3.44%

154 million

$6.2 billion

671.4 thousand

1.7 million

0.4

$8.96

$41.45

$41.55

01/29/2020

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Pimavanserin - CLARITY-2	Adjunctive Treatment in Patients With Major Depressive Disorder	Phase 3	Phase 3 data due 4Q 2020.
Pimavanserin - Advance	Adjunctive treatment in patients with negative symptoms of schizophrenia	Phase 2	Phase 2 data released November 25, 2019. Primary endpoint met. Key secondary missed. Further pivotal trial to be initiated 2H 2020.
Pimavanserin - Enhance	Adjunctive treatment of schizophrenia	Phase 3	Phase 3 data did not meet primary endpoint - July 22, 2019.
Pimavanserin - SERENE	Alzheimer’s disease agitation	Phase 2	Announced October 4, 2017 that trial will be discontinued.
Pimavanserin	Parkinson’s disease psychosis (PDP)	Approved	Approved April 29 2016. Additional dose approval announced June 29, 2018.
Pimavanserin - Harmony	Alzheimer’s disease psychosis	Phase 3	Phase 3 trial stopped early after meeting primary endpoint - September 9, 2019. Data presented at CTAD meeting December 4, 2019 noted HR =0.353, one-sided p=0.0023.
Trofinetide	Rett Syndrome	Phase 3	Phase 3 data due 2021.

ACER Acer Therapeutics Inc.

$4.00

  +0.00%

10.1 million

$40.4 million

7.2 thousand

59.2 thousand

0.12

$1.77

$4.11

$4.00

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
EDSIVO	Vascular Ehlers-Danlos Syndrome	CRL	CRL issued June 25, 2019.
Tovaxin (Tcelna)	Secondary Progressive MS (SPMS)	Phase 2b	Phase 2b trial did not meet primary endpoint - October 28, 2016.
ACER-001	Urea cycle disorder (UCD)	Phase 2	Pivotal bioavailability and bioequivalence trial Part B due 1Q 2020 with NDA filing 1Q 2021.
Osanetant	induced Vasomotor Symptoms (iVMS)	Phase 1/2	Phase 1/2 trial to be initiated mid-2020.

ACHV Achieve Life Sciences Inc.

$0.59

+0.03  +4.74%

25 million

$14.8 million

698.8 thousand

2.5 million

0.28

$0.61

$0.57

$0.56

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Cytisine	Smoking cessation	Phase 3	Phase 3 trial to be initiated 1H 2020.

ACIU AC Immune SA

$8.91

+0.11  +1.25%

71.7 million

$638.5 million

38.8 thousand

155.6 thousand

0.25

$2.02

$8.80

$8.80

01/29/2020

Tap to view 9 drug drugs

Drug	Indication	Stage	News
Crenezumab - CREAD 2	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
RG6100 (Anti-Tau RO7105705)	Alzheimer’s disease	Phase 2	Phase 2 data due 3Q 2020.
ACI-24 (anti-Abeta vaccine)	Alzheimer's disease-like characteristics in individuals with Down syndrome	Phase 1/2	Phase 1/2 interim data released July 2019.
Crenezumab - CREAD 1	Alzheimer’s disease	Phase 3	Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.
ACI-24	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced August 20, 2018.
MTAU9937A	Alzheimer’s disease	Phase 2	Phase 2 trial initiation announced February 20, 2019.
ACI-35	Alzheimer’s disease	Phase 1b	Phase 2 trial planned for 1H 2019.
ACI-3024	Alzheimer’s disease	Phase 1	Phase 1 trial initiation announced July 17, 2019.
ACI-35.030	Alzheimer’s Disease	Phase 1/2	Phase 1b/2 trial initiation announced August 1, 2019.

ACOR Acorda Therapeutics Inc.

$2.12

+0.01  +0.24%

48 million

$101.6 million

1.4 million

2.7 million

0.51

$0.36

$2.12

$2.11

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Ampyra	Improve walking in patients with multiple sclerosis		Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
CVT-427	Migraine	Phase 1	Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
Tozadenant	Parkinson’s disease (PD)	Phase 3	Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Dalfampridine	Post stroke deficits	Phase 3	Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
INBRIJA (CVT-301)	OFF episodes of Parkinson’s disease (PD)	Approved	FDA Approval announced December 22, 2018.
BTT1023	Primary Sclerosing Cholangitis	Phase 2	Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.

ACRS Aclaris Therapeutics Inc.

$1.35

-0.08  -5.59%

41.4 million

$55.9 million

287.3 thousand

659.5 thousand

0.44

$0.66

$1.44

$1.43

01/29/2020

Tap to view 8 drug drugs

Drug	Indication	Stage	News
ATI-502 (ATI-50002-AA-201) - dose ranging	Alopecia areata	Phase 2	Phase 2 data did not meet primary endpoint - June 26, 2019.
ATI-502 (VITI-201 Topical)	Vitiligo	Phase 2	Development to be discontinued - noted August 8, 2019.
ATI-501 (AUAT-201 Oral)	Alopecia areata	Phase 2	Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.
ESKATA (hydrogen peroxide)	Seborrheic keratosis (SK)	Approved	Approval announced December 15, 2017.
A-101 THWART-1 and THWART-2	Common warts (verruca vulgaris)	Phase 3	Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.
ATI-502	Androgenetic alopecia (AGA) - Hair loss	Phase 2	Partner required to further development.
ATI-502 (AD-201 Topical)	Atopic dermatitis (AD)	Phase 2	Phase 2 trial completed.
ATI-450	Rheumatoid arthritis (RA)	Phase 1/2	Phase 2 trial to be initiated 1H 2020.

ACRX AcelRx Pharmaceuticals Inc.

$1.76

-0.01  -0.28%

79.6 million

$140.4 million

350.1 thousand

980.2 thousand

0.36

-$4.90

$1.77

$1.77

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ARX-04 (SAP302)	Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury	Phase 3	Phase 3 data released August 15 2016
DSUVIA (ARX-04)	Moderate-to-severe acute pain following a surgical procedure	Approved	FDA Approval announced November 2, 2018.
Zalviso	Post-operative pain following open abdominal surgery and hip or knee replacement surgery	Phase 3	CRL Jul 26 2014. NDA resubmission timing to be known in 2H 2019.

ACST Acasti Pharma Inc.

$0.77

+0.03  +4.11%

89.2 million

$67.7 million

2.5 million

5.2 million

0.48

$58.49

$0.74

$0.74

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
CaPre (TRILOGY 1 and 2)	Hypertriglyceridemia	Phase 3	Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due mid-February 2020.

ADAP Adaptimmune Therapeutics plc

$4.22

+0.26  +6.57%

105.2 million

$443.8 million

1.6 million

2.3 million

0.68

$3.01

$4.08

$3.96

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
MAGE-A4 (ADP-A2M4)	Soild tumors	Phase 1	Phase 1 updated data noted one partial response - January 13, 2020.
AFP (ADP-A2AFP)	Hepatocellular carcinoma	Phase 1	Phase 1 data update noted one partial response - January 13, 2020.
MAGE-A10 (ADP-A2M10)	Non-Small Cell Lung Cancer (NSCLC)	Phase 1	Phase 1 enrolment to be completed by end of 2019.
MAGE-A4 (SPEARHEAD‑1)	Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)	Phase 2	Phase 2 interim futility data due 1H 2020.
MAGE-A4 (ADP-A2M4CD8 - SURPASS)	Soild tumors	Phase 1	Phase 1 safety and response data due 1H 2020.

ADIL Adial Pharmaceuticals Inc

$1.86

-0.1  -5.33%

10.3 million

$19.2 million

63.3 thousand

96.7 thousand

0.65

$2.19

$1.97

$1.97

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AD04	Alcohol use disorder	Phase 3	Phase 3 trial due to commence December 2019 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.

ADMA ADMA Biologics Inc

$4.18

+0.08  +1.95%

59.3 million

$248 million

418 thousand

784.6 thousand

0.53

$6.85

$4.10

$4.10

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
RI-002	Primary Immune Deficiency Diseases	Approved	FDA Approval announced April 1, 2019.
BIVIGAM	Primary humoral immunodeficiency	CRL	Response to Complete Response Letter submitted January 7, 2019.

ADMP Adamis Pharmaceuticals Corporation

$0.71

+0.02  +2.86%

61.6 million

$43.5 million

170.1 thousand

1.4 million

0.12

$1.08

$0.71

$0.69

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Epinephrine Pre-filled Syringe (PFS)	Emergency treatment of anaphylaxis.	Approved	CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.
APC-1000	Asthma/COPD	Phase 2	Phase 3 development on hold - noted May 9, 2019.
Symjepi - low dose	Anaphylaxis	Approved	FDA Approval announced September 27, 2018.
Higher Dose Naloxone Injection	Opioid overdose	CRL	CRL announced November 25, 2019.
APC-8000 (sublingual tadalafil)	Erectile dysfunction	NDA Filing	Refusal to file letter received February 26, 2019.

ADMS Adamas Pharmaceuticals Inc.

$5.32

+0.02  +0.30%

27.9 million

$148.1 million

162.7 thousand

721.1 thousand

0.23

$7.49

$5.32

$5.30

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ADS-4101	Partial onset seizures in patents with epilepsy	Phase 1b	Further development deferred - noted May 9, 2019.
GOCOVRI (amantadine)	Multiple sclerosis (MS)	Phase 3	Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019.
Namzaric	Moderate to severe dementia of the Alzheimer's type.	Approved	Approved December, 24 2014.
ADS-5102	Levodopa-Induced Dyskinesia	Approved	Approval announced August 24, 2017.
GOCOVRI (amantadine)	Dyskinesia patients with Parkinson's disease	Phase 3	Phase 3 open-label data released April 19, 2018.

ADRO Aduro Biotech Inc.

$1.40

-0.08  -5.41%

80.5 million

$112.7 million

405.9 thousand

948.1 thousand

0.43

$1.37

$1.47

$1.48

01/29/2020

Tap to view 7 drug drugs

Drug	Indication	Stage	News
CRS-207 and GVAX Pancreas - ECLIPSE trial	Pancreatic cancer	Phase 2b	Phase 2b primary endpoint not met - May 2016
ADU-214 with Nivolumab	Non-Small Cell Lung Cancer	Phase 1/2	Phase 1b initiation announced June 7, 2018.
ADU-S100 and Spartalizumab	Solid tumors or lymphomas	Phase 1b	Phase 1 trial to be discontinued - noted December 17, 2019.
ADU-S100 and ipilimumab	Melanoma	Phase 1	Phase 1 enrolment to be terminated - noted December 17, 2019.
BION-1301	IgA Nephropathy	Phase 1	Phase 1 data due 1H 2020 in healthy volunteers and 2H 2020 in IgA Nephropathy patients.
ADU-S100 and pembrolizumab	Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Phase 2	Phase 2 data due 2H 2020.
MK-5890 and pembrolizumab	Solid tumors	Phase 1	Phase 1 data presented at SITC November 2019 noted one patient in each of the monotherapy and combo arms showed a partial response.

ADVM Adverum Biotechnologies Inc.

$10.95

+0.28  +2.58%

64.6 million

$706.9 million

251.6 thousand

1.1 million

0.23

$4.31

$10.74

$10.67

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
ADVM-043	Alpha-1 Antitrypsin (A1AT) Deficiency	Phase 1/2	Development to be discontinued - noted November 1, 2018.
AVA-101	Wet age-related macular degeneration (Wet-AMD)	Phase 2a	Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.
ADVM-022	Wet age-related macular degeneration (Wet-AMD)	Phase 1	Phase 1 presentation of 24-week data from the second cohort and an update from first cohort of patients in the OPTIC trial due at the Angiogenesis Meeting, February 8, 2010 at 2:28 pm EST.

ADXS Advaxis Inc.

$0.68

-0.11  -13.78%

50.2 million

$34.4 million

5.1 million

8.5 million

0.61

$0.87

$0.80

$0.79

01/29/2020

Tap to view 7 drug drugs

Drug	Indication	Stage	News
Axalimogene filolisbac + durvalumab	Recurrent or refractory HPV-associated cervical cancer and head & neck cancer	Phase 1/2	Enrollment to be terminated - noted November 2, 2018.
ADXS-PSA and Keytruda - KEYNOTE-046	Castrate-resistant prostate cancer	Phase 1/2	Phase 1 updated data noted median overall survival of 33.6 months - October 7, 2019.
Axalimogene filolisbac - AIM2CERV Trial	High-risk, locally advanced cervical cancer	Phase 3	Phase 3 trial closed - noted June 27, 2019.
ADXS-HER2	HER2-driven malignancies - cancer	Phase 1b	Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.
Axalimogene filolisbac	Anal cancer (FAWCETT)	Phase 2	Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.
ADXS-NEO	Non-small cell lung cancer (NSCLC)	Phase 1	Phase 1 safety and immunogenicity data presented at AACR March 2019
ADXS-HOT 503	Non-small cell lung cancer (NSCLC)	Phase 1/2	Phase 1/2 immune response data from Part A monotherapy due 1Q 2020.

AERI Aerie Pharmaceuticals Inc.

$21.18

-0.35  -1.65%

46.3 million

$980.9 million

256.6 thousand

915.4 thousand

0.28

$4.68

$21.58

$21.53

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Roclatan	Glaucoma	Approved	FDA Approval announced March 12, 2019.
Rhopressa	Glaucoma	Approved	PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.
AR-13503	Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)	Phase 1/2	Phase 1/2 trial initiation announced August 20, 2019.
AR-1105	Macular edema due to RVO (retinal vein occlusion)	Phase 2	Phase 2 trial initiated March 2019.
Roclatan - Mercury 3	Open Angle Glaucoma	Phase 3	Phase 3 top-line data due mid-2020.
AVX-012	Dry eye disease	Phase 2b	Phase 2b trial to be initiated late-2020.

AEZS Aeterna Zentaris Inc.

$1.20

+0.04  +3.45%

20 million

$24 million

112.6 thousand

174.6 thousand

0.64

$43.95

$1.15

$1.16

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Macimorelin Acetate - Macrilen	Adult Growth Deficiency	Approved	CRL issued November 2014. Approval announced following resubmission December 20, 2017.
Zoptrex	Endometrial cancer	Phase 3	Phase 3 trial did not meet primary endpoint - May 1, 2017.

AFMD Affimed N.V.

$2.77

-0.01  -0.36%

76.2 million

$211.2 million

329.1 thousand

929.2 thousand

0.35

$8.66

$2.76

$2.78

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AFM13 with Keytruda	Hodgkin Lymphoma - Cancer	Phase 1b	Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.
AFM13	Hodgkin Lymphoma - Cancer	Phase 2	Phase 2a ongoing.
AFM13	CD30-positive peripheral T cell lymphoma (PTCL)	Phase 2	Phase 2 dosing has been initiated - noted November 19, 2019.
AFM11	Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)	Phase 1	Phase 1 program terminated - noted May 22, 2019.
AFM24	EGFR-expressing solid tumors	Phase 1/2	Phase 1/2a trial to commence 1Q 2020.

AGEN Agenus Inc.

$3.78

+0.07  +2.02%

137.4 million

$519.2 million

1.5 million

1.3 million

1.2

-$2.61

$3.70

$3.70

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
AGEN2034 and AGEN1884	Solid tumors	Phase 1/2	Phase 1/2 trial ongoing.
Zalifrelimab - AGEN1884 (anti-CTLA-4)	Solid cancers	BLA Filing	BLA filing due 2020.
Shingrix	Shingles	Approved	Approval announced October 20, 2017.
AGEN2034 (anti-PD-1)	Cervical cancer	Phase 1/2	Subset analysis of Phase I dose escalation trial presented at SITC November 8, 2019.
AGEN1181 - 2nd gen CTLA	Advanced cancer	Phase 1	Phase 1 combination with balstilimab trial initiation announced December 19, 2019.

AGIO Agios Pharmaceuticals Inc.

$53.35

+0.79  +1.50%

68.4 million

$3.6 billion

152.7 thousand

861.1 thousand

0.18

$8.13

$52.58

$52.56

01/29/2020

Tap to view 18 drug drugs

Drug	Indication	Stage	News
AG-348 - Mitapivat	Thalassemia	Phase 2	Phase 2 updated data due at EHA June 11 - 14, 2020.
Ivosidenib	IDH1m Relapsed/Refractory AML - cancer	Approved	FDA Approval announced July 20, 2018.
AG-348 (ACTIVATE)	Pyruvate kinase deficiency	Phase 3	Phase 3 enrolment to be completed 2019.
AG-120 and VIDAZA - AGILE	Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer	Phase 3	Phase 3 enrolment to be completed 2020.
Enasidenib (AG-221) - IDHENTIFY	Refractory Acute myeloid leukemia (AML) - cancer	Phase 3	Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
IDHIFA (enasidenib) - AG-221	Advanced hematologic malignancies with an IDH2 mutation	Approved	Approval announced August 1, 2017.
AG-120 Ivosidenib (ClarIDHy)	IDH1 mutant positive cholangiocarcinoma - cancer	Phase 3	sNDA filing due to be filed following final overall survival analysis mid-2020.
AG-120 Ivosidenib	R/R Acute Myeloid Leukemia (AML)	Phase 1	Phase 1 data at ASCO June 2018 noted CR rate was 24%.
Enasidenib or ivosidenib with VIDAZA	Frontline AML with IDH1 or IDH2 mutation	Phase 1/2	Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.
Ivosidenib or enasidenib	Frontline AML with IDH1 or IDH2 mutation	Phase 1	Phase 1 updated data at ASH December 2018. CR+CRi/CRp 80%.
AG-270	Solid tumors	Phase 1	Phase 1 data presented at AACR-NCI-EORTC October 27, 2019. Trial is ongoing.
Vorasidenib (AG-881)	Glioma	Phase 3	Phase 3 trial to be initiated YE 2019.
Ivosidenib	Frontline AML with IDH1 mutation	Approved	FDA Approval announced May 2, 2019.
Ivosidenib and Vorasidenib (AG-881)	IDHm low-grade glioma	Phase 1	Phase 1 updated data noted 31% ORR with postoperative treatment - November 22, 2019.
Ivosidenib	IDH1 mutant newly diagnosed AML ineligible for standard therapies	Phase 1	Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.
Ivosidenib and azacitidine ( Vidaza)	Newly diagnosed AML with an IDH1 mutation	Phase 1	Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.
AG-348 - Mitapivat (ACTIVATE)	Pyruvate Kinase Deficiency	Phase 3	Phase 3 data due by the end of 2020.
AG-348 - Mitapivat	Sickle cell disease.	Phase 1	Phase 1 data due mid-2020.

AGLE Aeglea BioTherapeutics Inc.

$7.27

+0.01  +0.14%

29 million

$210.7 million

32.9 thousand

60.7 thousand

0.54

$2.64

$7.21

$7.26

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AEB1102	Acute myeloid leukemia (AML) or Myelodysplastic syndromes (MDS)	Phase 1	Phase 1 initiation announced July 2016. Enrollment to be completed in 2017.
Pegzilarginase (AEB1102)	Arginase I deficiency	Phase 3	Phase 3 trial initiation announced June 3, 2019 with data due 1Q 2021.
AEB1102	Solid tumors	Phase 1	Phase 1 dose escalation data presented at AACR April 15, 2018.
Pegzilarginase (AEB1102)	Solid tumors	Phase 1	Phase 1 data presented at ESMO October 2018 noted 1/28 PRs and 8/23 SD.
Pegzilarginase (AEB1102) + KEYTRUDA	Small cell lung cancer (SCLC)	Phase 2	Phase 1/2 trial ongoing.
AEB4104	Homocystinuria	Phase 1/2	Phase 1/2 trial to be initiated 2Q 2020 with initial data due 1Q 2021.

AGN Allergan plc

$189.34

+0.09  +0.05%

328.3 million

$62.2 billion

7.38

761.7 thousand

2.4 million

0.31

$1.06

$189.28

$189.25

01/29/2020

Tap to view 28 drug drugs

Drug	Indication	Stage	News
Botox	Forehead lines	Approved	Approval (third indication) announced October 3, 2017.
RTGel in combination with BOTOX	Overactive Bladder (OAB)	Phase 2	Phase 2 trial ongoing.
JUVÉDERM VOLLURE	Correction of moderate to severe facial wrinkles and folds	Approved	Approval announced March 20, 2017.
Botox	Depression	Phase 2	Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
RORγt agonist	Psoriasis	Phase 2b	Phase 2b trial ongoing.
Cariprazine	Maintenance Treatment of Schizophrenia	Approved	Approval announced November 13, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	BLA Filing	BLA filing announced December 19, 2019.
ATOGEPANT	Chronic migraine	Phase 3	Phase 3 data due in 2020.
RAPASTINEL	Major depressive disorder (MDD)	Phase 3	Phase 3 trials did not meet primary endpoints - March 6, 2019.
RELAMORELIN	Diabetic Gastroparesis	Phase 3	Phase 3 top-line data due 2020.
ESMYA (ulipristal acetate)	Uterine Fibroids	CRL	CRL issued August 21, 2018.
ABICIPAR	Diabetic macular edema (DME)	Phase 3	Phase 3 trial to be initiated 2019.
Cenicriviroc (CVC)	Nonalcoholic steatohepatitis (NASH)	Phase 3	Phase 3 data due 2020.
ABICIPAR	Age-related macular degeneration (AMD)	PDUFA priority review	BLA acceptance of filing announced September 9, 2019. Estimated PDUFA date July 9, 2020.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI)	Approved	sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
Oxymetazoline HCl cream 1.0%	Facial Erythema (Redness) Associated with Rosacea	Approved	Approved January 19, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults	Chronic idiopathic constipation (CIC)	Approved	sNDA approval announced January 26, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	Approved	Approved September 14, 2017.
Sarecycline	Severe acne vulgaris	Approved	FDA Approval announced October 2, 2018.
Cariprazine	Bipolar I Depression	PDUFA	FDA Approval announced May 28, 2019.
Ubrogepant	Migraine	Approved	FDA Approval announced December 23, 2019.
Brimo DDS	Geographic atrophy	Phase 3	Phase 3 trial to be initiated 2H 2018.
Bimatoprost	Open-angle glaucoma or ocular hypertension	PDUFA	PDUFA date 1H 2020. No exact date announced. Estimate May 15, 2020.
AVYCAZ (ceftazidime and avibactam)	Complicated Urinary Tract Infections (cUTI) - pediatric	Approved	FDA Approval announced March 18, 2019.
Botox	Lower limb spasticity	Approved	FDA Approval announced October 24, 2019.
Botox	Upper limb spasticity	Approved	FDA Approval announced June 21, 2019.
Presbysol	Presbyopia	Phase 3	Phase 3 top-line data due 2020.
Juvéderm VOLUMA	Mid-Face Injection Via Cannula	Approved	FDA Approval announced September 3, 2019.

AGRX Agile Therapeutics Inc.

$3.77

-0.15  -3.95%

69.8 million

$262.8 million

5.6 million

3.2 million

1.76

$6.97

$4.10

$3.92

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Twirla	Contraceptive patch	PDUFA	CRLs issued 2013 and 2017. New PDUFA extended by three months to February 16, 2020. Advisory Committee Meeting October 30, 2019 voted 14 to 1 in favor.

AGTC Applied Genetic Technologies Corporation

$7.30

+0.03  +0.41%

18.2 million

$133 million

124.6 thousand

1.4 million

0.09

$1.96

$7.25

$7.27

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
AAV Gene Therapy	Achromatopsia	Phase 1/2	Phase 1/2 interim data from pediatric patients due 2H 2020.
rAAV-hRS1	X-linked retinoschisis (XLRS)	Phase 1/2	Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.
AAV-based gene therapy	X-linked Retinitis Pigmentosa (XLRP)	Phase 1/2	Phase 1/2 positive dose expansion data released January 9, 2020.

AIM AIM ImmunoTech Inc.

$0.93

-0.08  -7.91%

8.3 million

$7.7 million

0.19

839 thousand

1.2 million

0.7

$0.59

$1.00

$1.01

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
Ampligen	CFS	CRL	CRL February 4, 2013.
Ampligen, Intron A, celecoxib and pembrolizumab	Triple-Negative Breast Cancer	Phase 1	Phase 1 data due around 2Q 2020.
Ampligen, Intron A, and celecoxib	Colorectal cancer	Phase 2	Phase 2 interim data due around 2Q 2020.
Ampligen, cisplatin and pembrolizumab	Ovarian cancer	Phase 2	Phase 2 interim data due around 4Q 2020.
Ampligen, Intron A	Prostate Cancer	Phase 2	Phase 2 trial to commence enrolment in 4Q 2019.
Ampligen plus Intron A	Ovarian cancer	Phase 1/2	Phase 1 interim data to be presented 1Q 2020.

AIMT Aimmune Therapeutics Inc.

$32.46

-0.36  -1.10%

63.3 million

$2.1 billion

484.6 thousand

945 thousand

0.51

$13.47

$33.06

$32.82

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AR101 ARTEMIS	Peanut Allergy	Phase 3	Phase 3 trial met primary endpoint - March 25, 2019.
AR101 RAMSES	Peanut Allergy	Phase 3	Phase 3 data released November 8, 2018 noted no serious adverse events
AR101	Peanut Allergy	PDUFA	Advisory Committee meeting September 13, 2019 voted in favor of supporting approval. PDUFA date late-January 2020.
AR 201	Egg Allergy	Phase 2	Phase 2 trial to be completed 2H 2020.
AR101 with adjunctive dupilumab	Peanut Allergy	Phase 2	Phase 2 trial initiation announced October 15, 2018.
AR101 POSEIDON	Peanut Allergy	Phase 3	Phase 3 data due 2020.

AKBA Akebia Therapeutics Inc.

$7.82

-0.01  -0.19%

118.9 million

$929.5 million

417.4 thousand

1.7 million

0.25

$1.99

$7.82

$7.83

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
Vadadustat - TRILO2GY	Three-times-weekly dosing regimen for vadadustat	Phase 3	Phase 3 trial to be initiated in 2019.
Auryxia	Hyperphosphatemia	Approved	Approved Sept 5, 2014.
Vadadustat - INNO2VATE	Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)	Phase 3	Phase 3 data due 2Q 2020.
Vadadustat - PRO2TECT	Non-dialysis patients with anemia related to CKD (NDD-CKD)	Phase 3	Phase 3 data due mid-2020.
Auryxia	Iron deficiency anemia in non-dialysis dependent CKD patients	Approved	sNDA FDA Approval announced November 7, 2017.

AKCA Akcea Therapeutics Inc.

$18.64

-0.21  -1.11%

100.8 million

$1.9 billion

118.3 thousand

303 thousand

0.39

$5.37

$18.68

$18.85

01/29/2020

Tap to view 10 drug drugs

Drug	Indication	Stage	News
AKCEA-ANGPTL3-LRx	Rare hyperlipidemias	Phase 2	Pilot study data due mid-2019.
AKCEA-ANGPTL3-LRx	Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus	Phase 2b	Phase 2b data met primary endpoint - January 28, 2020.
AKCEA-APOCIII-LRx	Hyperlipoproteinemia and established cardiovascular disease	Phase 2	Phase 2 data met primary and secondary endpoints - January 22, 2020.
AKCEA-APO(a)-LRx	Hyperlipoproteinemia(a) and established cardiovascular disease	Phase 2b	Phase 3 trial to be initiated 2H 2019.
Inotersen (IONIS-TTRRx)	NEURO-TTR - familial amyloid polyneuropathy (FAP).	Approved	FDA Approval announced October 5, 2018,
Volanesorsen - APPROACH	Familial chylomicronemia syndrome (FCS)	CRL	CRL issued August 27, 2018.
Volanesorsen	Partial lipodystrophy rapidly	Phase 3	Phase 3 initiated November 2015
Volanesorsen	Familial partial lipodystrophy (FPL)	Phase 3	Phase 3 data met primary endpoint - August 6, 2019.
AKCEA-TTR-LRx	hATTR Amyloidosis	Phase 3	Phase 3 trial initiation announced November 25, 2019.
AKCEA-TTR-LRx - CARDIO-TTRansform	ATTR cardiomyopathy	Phase 3	Phase 3 trial initiation announced January 10, 2020.

AKRO Akero Therapeutics Inc.

$24.19

+0.49  +2.07%

28.6 million

$690.8 million

25.6 thousand

174.5 thousand

0.15

$4.82

$23.50

$23.70

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
AKR-001	Nonalcoholic steatohepatitis (NASH)	Phase 2a	Phase 2a data due 1Q 2020 (MRI‐PDFF).

AKTX Akari Therapeutics Plc

$1.83

-0.02  -1.08%

21 million

$38.4 million

74.2 thousand

441.4 thousand

0.17

$12.20

$1.86

$1.85

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
Nomacopan - CAPSTONE	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 3	Phase 3 interim data January 10, 2020 noted all patients achieved the primary endpoint of transfusion independence. Further data due at EHA June 11-14, 2020.
Nomacopan	Atopic keratoconjunctivitis	Phase 1/2	Phase 1/2 Part B data due 1Q 2020.
Coversin	Bullous Pemphigoid	Phase 2	Phase 2 data presented at EADV Congress with a pivotal trial to commence 2H 2020.
Nomacopan	Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)	Phase 3	Phase 3 trial initiation announced December 23, 2019.

ALBO Albireo Pharma Inc.

$24.08

-0.19  -0.78%

12.7 million

$305.5 million

19.9 thousand

83.9 thousand

0.24

$3.01

$24.40

$24.27

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Odevixibat (A4250) - PEDFIC- 1	Progressive familial intrahepatic cholestasis (PFIC)	Phase 3	Phase 3 top-line data due mid-2020.
Elobixibat	Nonalcoholic steatohepatitis (NASH)	Phase 2	Phase 2 data due mid-2020.
Odevixibat (A4250)	Biliary atresia	Phase 3	Phase 3 trial planned for 2020.

ALDX Aldeyra Therapeutics Inc.

$5.67

-0.12  -2.07%

28 million

$158.5 million

73.5 thousand

320.6 thousand

0.23

$3.12

$5.87

$5.79

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
ADX-102 - topical ocular reproxalap - RENEW	Dry eye syndrome	Phase 3	Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Part 2 to be initiated 1H 2020.
Reproxalap (ADX-102) - INVIGORATE	Allergic conjunctivitis	Phase 3	Phase 3 enrolment has commenced - January 21, 2020.
ADX-102 reproxalap	Noninfectious anterior uveitis	Phase 3	Phase 3 data did not meet endpoints - June 25, 2019.
Reproxalap (ADX-102)	Sjögren-Larsson Syndrome (SLS)	Phase 3	Phase 3 Part 1 section of trial completed.
ADX-1612 (ganetespib)	Post-transplant lymphoproliferative disorder	Phase 2	Phase 2 trial to be initiated 4Q 2019.
ADX-2191	Proliferative vitreoretinopathy (PVR)	Phase 3	Phase 3 commencement of enrolment announced December 19, 2019 with initial data due 2020.

ALEC Alector Inc.

$26.47

+1.88  +7.64%

68.9 million

$1.8 billion

426.5 thousand

452.7 thousand

0.94

$8.35

$25.11

$24.59

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AL001	Frontotemporal Dementia	Phase 2	Phase 2 data due 1H 2020.
AL002	Alzheimer’s disease	Phase 1b	Phase 1b proof of mechanism data due in 2020.
AL003	Alzheimer’s disease	Phase 1	Phase 1b proof of mechanism data due in 2020.
AL101	Healthy volunteers	Phase 1	Phase 1 initiation of dosing announced January 6, 2020.

ALIM Alimera Sciences Inc.

$6.91

-0.22  -3.09%

5 million

$34.3 million

7.7 thousand

75.9 thousand

0.1

-$0.93

$7.25

$7.13

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Iluvien	Diabetic macular edema	Approved	CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014

ALKS Alkermes plc

$17.91

+0.14  +0.76%

157.5 million

$2.8 billion

436 thousand

1.7 million

0.26

$2.64

$17.85

$17.77

01/29/2020

Tap to view 13 drug drugs

Drug	Indication	Stage	News
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)	Schizophrenia	Approved	FDA approval announced July 2, 2018.
ALKS 3831	Schizophrenia, bipolar	PDUFA	PDUFA date November 15, 2020.
BYDUREON	Type 2 diabetes	Approved	CRL received March 15, 2010.
Aristada	Schizophrenia	Approved	Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
Diroximel fumarate (BIIB098)	Multiple sclerosis (MS)	Approved	FDA Approval announced October 30, 2019.
ALKS 6428	Opioid dependence	Phase 3	Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 5461	Major depressive disorder	CRL	CRL announced February 1, 2019.
ALKS 3831 - ENLIGHTEN-1	Schizophrenia	Phase 3	Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
ALKS 4230 ARTISTRY-1	Solid tumors	Phase 1	Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).
Aristada and Invega Sustenna	Schizophrenia	Phase 3	Phase 3 data released April 9, 2019 - primary endpoint met.
ALKS 4230 + Keytruda - ARTISTRY-2	Solid tumors	Phase 1	Phase 1 data presented at SITC November 8, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -	Relapsing Remitting Multiple Sclerosis (RRMS)	Phase 3	Phase 3 top-line data met primary endpoint - July 30, 2019.
ALKS 4230 + Keytruda (ION-01)	Head and neck squamous cell cancer	Phase 2	Phase 2 trial to be initiated 4Q 2019.

ALLK Allakos Inc.

$76.05

-1.4  -1.81%

48.7 million

$3.7 billion

312.5 thousand

496.2 thousand

0.63

$7.20

$77.55

$77.45

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
AK002	Severe Allergic Conjunctivitis	Phase 1	Phase 1 data May 7, 2019 noted a 78% median improvement in ocular symptoms
AK002	Indolent Systemic Mastocytosis	Phase 1	Phase 1 data released February 19, 2019.
AK002	Chronic Urticaria	Phase 2	Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.
AK002	Eosinophilic Gastritis	Phase 2	Phase 2 top-line data met primary and secondary endpoints - August 5, 2019. Extension data due 1H 2020. Phase 3 trial to commence 1Q 2020.

ALLO Allogene Therapeutics Inc.

$22.18

-0.39  -1.73%

121.9 million

$2.7 billion

428.2 thousand

666 thousand

0.64

$4.37

$22.60

$22.57

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
UCART19 (PALL)	Acute lymphoblastic leukemia (ALL)	Phase 1	Phase 2 trial to be initiated in 2020.
UCART19 - CALM	Refractory B-cell Acute Lymphoblastic Leukaemia	Phase 1	Phase 1 trial ongoing.
ALLO-715	Multiple myeloma	Phase 1/2	Phase 1/2 trial initiated 3Q 2019.
ALLO-501 - ALPHA	Non-Hodgkin lymphoma (NHL)	Phase 1	Phase 1 initial data due 1H 2020.
ALLO-715 with nirogacestat	Multiple myeloma	Phase 1	Phase 1 trial to commence 2H 2020.

ALNA Allena Pharmaceuticals Inc.

$2.50

+0.31  +14.16%

23.5 million

$58.7 million

353.4 thousand

347.8 thousand

1.02

$2.34

$2.23

$2.19

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Reloxaliase ALLN-177 (URIROX-1)	Enteric Hyperoxaluria	Phase 3	Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019.
Reloxaliase ALLN-177 (Study 206)	Primary hyperoxaluria	Phase 2	Phase 2 presentation at ASN November 8, 2019.
Reloxaliase ALLN-177 (URIROX-2)	Enteric Hyperoxaluria	Phase 3	Phase 3 data due 2H 2021. Noted December 4, 2019 that it intends to discuss with the FDA a proposal to reduce target enrolment and conduct an earlier interim analysis.

ALNY Alnylam Pharmaceuticals Inc.

$118.14

+3.42  +2.98%

111.5 million

$13.2 billion

276.4 thousand

780.3 thousand

0.35

$8.20

$114.71

$114.72

01/29/2020

Tap to view 16 drug drugs

Drug	Indication	Stage	News
Givosiran	Acute hepatic porphyrias	Approved	FDA approval announced November 20, 2019.
Inclisiran - ORION-9	Hypercholesterolemia	Phase 3	Phase 3 data met all endpoints - September 25, 2019. Data November 18, 2019 noted LDL-C reductions of 50%.
ALN-HBV02 (VIR-2218)	Chronic hepatitis B virus (HBV)	Phase 1/2	Phase 1/2 additional data due 1H 2020.
Lumasiran (ALN-GO1) ILLUMINATE-A	Primary Hyperoxaluria Type 1 (PH1)	NDA Filing	Rolling NDA filing has been initiated - January 10, 2020. To be completed early-2020.
Patisiran	Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR	Approved	FDA Approval announced August 10, 2018.
ALN-CC5 (cemdisiran)	IgA nephropathy	Phase 2	Phase 2 trial ongoing.
Fitusiran (ATLAS)	Hemophilia	Phase 3	Phase 3 ongoing.
ALN-TTRsc02 - HELIOS-A	ATTR amyloidosis	Phase 3	Phase 3 trial enrolling - noted December 6, 2018.
Inclisiran - ORION-10	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 data met all endpoints - September 25, 2019. Detailed data due at AHA noted 58% LDL-C lowering.
Inclisiran - ORION 11	Cardiovascular disease (ASCVD)	Phase 3	Phase 3 trial met all primary and secondary efficacy endpoints. Noted September 2, 2019 a 54% LDL-C lowering after 11 months and 50% over 18 months.
ALN-AAT02	alpha-1 anti-trypsin deficiency-associated liver disease	Phase 1/2	Phase 1/2 data due late-2019. Moved to 1Q 2020 due to no update.
Lumasiran (ALN-GO1) ILLUMINATE-B	Primary Hyperoxaluria Type 1	Phase 3	Phase 3 top-line data due mid-2020.
Patisiran APOLLO-B	Wild-type ATTR amyloidosis patients with cardiomyopathy	Phase 3	Phase 3 enrolment to be completed late-2020.
Lumasiran (ALN-GO1) ILLUMINATE-C	Impaired renal function	Phase 3	Phase 3 trial data due end of 2020.
ALN-AGT	Hypertension	Phase 1	Phase 1 trial ongoing.
ALN-TTRsc02 (vutrisiran) - HELIOS-B	ATTR amyloidosis with cardiomyopathy	Phase 3	Phase 3 trial has been initiated - noted November 22, 2019.

ALPN Alpine Immune Sciences Inc.

$2.97

+0.07  +2.41%

18.6 million

$55.2 million

4.4 thousand

19.3 thousand

0.23

$1.59

$3.00

$2.90

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
N91115	Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein	Phase 2	Phase 2 data released February 24, 2017 - primary endpoint not met.
ALPN-101	Healthy volunteers	Phase 1	Phase 1 presentation at ASH December 8, 2019.
ALPN-202	Advanced Malignancies	Phase 1	Phase 1 trial to be initiated 1Q 2020.

ALRN Aileron Therapeutics Inc.

$0.73

  +0.05%

27.8 million

$20.3 million

96.5 thousand

323.2 thousand

0.3

$0.89

$0.75

$0.73

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ALRN-6924	Peripheral T-cell lymphoma (PTCL)	Phase 2a	Noted that development to be discontinued - no pivotal trial.
ALRN-6924 and Cytarabine (Ara-C)	Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)	Phase 1b	Phase 1/1b trial ongoing.
ALRN-6924 and IBRANCE (palbociclib)	Solid tumors	Phase 2a	Phase 2a final data due 2Q 2020.
ALRN-6924 and Paclitaxel	Breast cancer	Phase 1	Phase 1 has been initiated.
ALRN-6924	Small Cell Lung Cancer (SCLC)	Phase 1/2	Phase 1b/2 dose-optimization data due 2Q 2020.

ALT Altimmune Inc.

$1.84

+0.01  +0.55%

15.3 million

$28.2 million

143.2 thousand

231.7 thousand

0.62

$0.57

$1.82

$1.83

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
HepTCell	Hepatitis B	Phase 1	Phase 2 trial planned for 2020.
NasoVAX	Flu vaccine	Phase 2	Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NASOSHIELD	Anthrax	Phase 1b	Phase 1b trial to be initiated in 1Q 2020.
ALT-801	Non-alcoholic steatohepatitis (NASH)	Phase 1	IND to be filed in 2020 with Phase 1 data due 2021.

ALXN Alexion Pharmaceuticals Inc.

$108.64

+1.67  +1.56%

221.3 million

$24 billion

903.2 thousand

1.8 million

0.5

$2.32

$107.13

$106.97

01/29/2020

Tap to view 18 drug drugs

Drug	Indication	Stage	News
CAEL‐101	AL amyloidosis	Phase 2/3	Phase 2b/3 trial to be initiated 1H 2020 with data due in 2021.
ACH-4471	C3 glomerulopathy (C3G)	Phase 2	Phase 2 completion due 2020.
Eculizumab	Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Approved	FDA Approval announced June 27, 2019.
ULTOMIRIS (ravulizumab-cwvz)	atypical Hemolytic Uremic Syndrome (aHUS)	Approved	FDA Approval announced October 18, 2019.
ULTOMIRIS (ravulizumab-cwvz)	Paroxysmal nocturnal hemoglobinuria (PNH)	Approved	FDA approval announced December 21, 2018.
Eculizumab	Refractory generalized myasthenia gravis (gMG)	Approved	Approval announced October 23, 2017.
Danicopan (ACH-4471)	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 3	Phase 3 trial to be initiated early 2020.
ACH-5228	Paroxysmal nocturnal hemoglobinuria (PNH)	Phase 1	Phase 2 trial planned to commence 1H 2020.
ALXN1840 (WTX101)	Wilson disease	Phase 3	Phase 3 top-line data due 1H 2021.
ULTOMIRIS (ravulizumab-cwvz)	Generalized myasthenia gravis (gMG)	Phase 3	Phase 3 trial initiated 1Q 2019.
ALXN1830	Warm autoimmune hemolytic anemia (WAIHA)	Phase 1/2	Phase 2/3 trial to be initiated early 2020.
ULTOMIRIS (ravulizumab-cwvz) subcutaneous	Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)	Phase 3	Phase 3 PK data due 1H 2020.
Elamipretide	Leber’s hereditary optic neuropathy (LHON)	Phase 2	Phase 2 trial did not meet primary endpoint. Phase 3 trial planned for 2020.
Elamipretide	Primary mitochondrial myopathy	Phase 3	Phase 3 data did not meet primary endpoint - December 20, 2019.
ULTOMIRIS	Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)	Phase 3	Phase 3 trial to commence 1H 2020.
Eculizumab	Generalized myasthenia gravis (gMG) - children	Phase 3	Phase 3 trial has commenced - noted October 23, 2019.
Eculizumab	Neuromyelitis Optica Spectrum Disorder (NMOSD) - children	Phase 3	Phase 3 trial to commence by the end of 2019.
ULTOMIRIS (ravulizumab) - CHAMPION-ALS	Amyotrophic lateral sclerosis (ALS)	Phase 3	Phase 3 trial initiation due 1Q 2020.

AMAG AMAG Pharmaceuticals Inc.

$9.93

+0.29  +3.01%

33.9 million

$336.8 million

335.2 thousand

793.7 thousand

0.42

$0.70

$9.93

$9.64

01/29/2020

Tap to view 6 drug drugs

Drug	Indication	Stage	News
AMAG-423 / Digoxin immune fab (DIF)	Severe preeclampsia in pregnant women	Phase 2/3	Phase 2/3 top-line data due 1H 2020.
Vyleesi (Bremelanotide)	Female sexual dysfunction (FSD)	Approved	FDA approval announced June 21, 2019.
Feraheme	Adults with iron deficiency anemia (IDA)	Approved	Approval for sNDA filing announced February 5, 2018.
Makena - auto injector	Reduce the risk of preterm birth in women with a singleton pregnancy	Approved	Approval announced February 14, 2018.
Makena	Preterm birth	Phase 3	Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.
Ciraparantag	Anticoagulated reversal agent / Healthy volunteers	Phase 2	End of Phase 2 trial meeting slated for 2H 2020.

AMGN Amgen Inc.

$228.79

+3.95  +1.76%

594.2 million

$135.9 billion

1.1 million

2.2 million

0.48

$12.44

$225.50

$224.84

01/29/2020

Tap to view 34 drug drugs

Drug	Indication	Stage	News
Tezepelumab - NAVIGATOR	Asthma	Phase 3	Phase 3 data due late-2020.
Prolia (denosumab)	Glucocorticoid-induced osteoporosis (GIOP)	Approved	Approval announced May 21, 2018.
KYPROLIS (ASPIRE)	Relapsed Multiple Myeloma	Approved	sNDA approval announced June 11, 2018.
Vectibix (Panitumumab)	Wild-Type RAS Metastatic Colorectal Cancer	Approved	sBLA approval announced June 29, 2017.
MVASITM (bevacizumab-awwb)	Biosimilar candidate to Avastin (bevacizumab)	PDUFA	Approved September 14, 2017.
Corlanor	Chronic Heart Failure	Approved	Approved April 15, 2015.
Erenumab	Migraine	Approved	Approval announced May 17, 2018.
OTEZLA	Scalp Psoriasis	sNDA Filing	sNDA filing pending.
OTEZLA - PSA-006	Psoriatic Arthritis	Phase 3	Phase 3 - primary endpoint met.
OTEZLA	Behçet’s Disease	Approved	FDA Approval announced July 19, 2019.
Repatha	Cardiovascular disease	Approved	Approval announced December 1, 2017.
XGEVA	Multiple Myeloma	Approved	sBLA approval announced January 5, 2017.
KYPROLIS (ARROW)	Multiple Myeloma	Approved	FDA approval announced October 1, 2018.
KYPROLIS (ENDEAVOR)	Relapsed Multiple Myeloma	Approved	sNDA approved January 17, 2018.
BLINCYTO	Ph+ R/R ALL	Approved	PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.
ABP 798	RITUXAN biosimilar - non-Hodgkin lymphoma	BLA Filing	BLA filing announced December 19, 2019.
ABP 980 (Kanjinti; trastuzumab-anns)	Herceptin biosimilar	CRL	FDA approval announced June 13, 2019.
ABP 710	REMICADE biosimilar - rheumatoid arthritis	Approved	FDA Approval announced December 6, 2019.
Parsabiv	Secondary hyperparathyroidism (SHPT)	Approved	Approved February 7, 2017.
EVENITY (Romosozumab)	Osteoporosis	Approved	FDA Approval announced April 9, 2019.
Omecamtiv mecarbil GALACTIC-HF	Acute heart failure	Phase 3	Phase 3 second interim analysis due 1Q 2020. Top-line data due 4Q 2020.
Omecamtiv mecarbil METEORIC-HF	Acute heart failure	Phase 3	Second Phase 3 trial initiation announced February 21, 2019. Enrolment to continue through 2020.
AMG 420	Relapsed. Refractory (R/R) Multiple Myeloma (MM)	Phase 1	Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.
AMG 330	Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	Phase 1	Phase 1 data at ASH December 1, 2018 noted 12.5% ORR.
Nplate (Romiplostim)	Immune Thrombocytopenia (Pediatric)	Approved	FDA approval announced December 14, 2018.
Nplate (Romiplostim)	Immune thrombocytopenia (ITP)	Approved	FDA Approval announced October 18, 2019.
KYPROLIS (CANDOR)	Multiple Myeloma	Phase 3	Phase 3 data met primary endpoint - September 13, 2019. LBA at ASH December 10, 2019. PFS HR=0.63. ORR 84.3%. CR 28.5%.
OTEZLA - ADVANCE	Plaque psoriasis	Phase 3	Phase 3 trial is initiating.
AMG 594	Healthy volunteers	Phase 1	Phase 1 trial to be completed 2H 2020.
AMG 510	Solid tumors	Phase 1	Phase 1 update at ESMO noted 54% PR rate for NSCLC patients (960mg); 1/12 for CRC patients. Next update due in 2020.
CNP520	Alzheimer’s Disease	Phase 2/3	Phase 2/3 trial discontinued due to lack of efficacy.
BLINCYTO	Acute lymphoblastic leukemia (ALL) - pediatric	Phase 3	Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.
AMG 570	Systemic Lupus Erythematosus (SLE)	Phase 2	Phase 2 trial is enrolling.
Tezepelumab	Chronic obstructive pulmonary disease (COPD)	Phase 2	Phase 2 trial is enrolling.

AMPE Ampio Pharmaceuticals Inc.

$0.69

+0.01  +1.46%

158.6 million

$109.5 million

11.4

792.2 thousand

1.1 million

0.71

$23.00

$0.68

$0.68

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Ampion	Osteoarthritis of the Knee	Phase 3	As of July 24, 2019 enrolment has reached approximately 30%.
Optina	Diabetic Macula Edema	Phase 2b	Phase 2b data released May 2015 did not meet endpoints

AMPH Amphastar Pharmaceuticals Inc.

$20.04

+0.32  +1.62%

46.9 million

$940.6 million

110.1 thousand

235.4 thousand

0.47

$2.41

$19.70

$19.72

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Albuterol DPI	Asthma	Phase 2b
Naloxone Intranasal	Opioid overdose	CRL	CRL announced February 21, 2017.
Primatene Mist (epinephrine inhalation aerosol)	Asthma	CRL	CRL issued December 27, 2016.

AMRN Amarin Corporation plc

$19.82

-0.44  -2.17%

358.9 million

$7.1 billion

4.7 million

12 million

0.39

$12.39

$20.06

$20.26

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Vascepa	High Triglycerides With Mixed Dyslipidemia	Approved	FDA Approval announced December 13, 2019.

AMRX Amneal Pharmaceuticals Inc. Class A

$4.68

-0.01  -0.32%

299.1 million

$1.4 billion

0.88

408.5 thousand

3.3 million

0.12

$6.42

$4.70

$4.70

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
IPX203	Parkinson's disease	Phase 3	Phase 3 data due 1H 2020.
K127	Myasthenia Gravis	NDA Filing	NDA filing planned.

ANAB AnaptysBio Inc.

$14.30

-0.36  -2.46%

27.1 million

$388 million

119.6 thousand

800.1 thousand

0.15

$0.92

$14.62

$14.66

01/29/2020

Tap to view 5 drug drugs

Drug	Indication	Stage	News
ANB020 - etokimab	Moderate-to-severe adult atopic dermatitis	Phase 2b	Phase 2b data failed to meet primary endpoint - November 8, 2019.
ANB020 - etokimab	Severe adult eosinophilic asthma	Phase 2a	Phase 2b trial initiation postponed.
ANB019 - POPLAR	Palmo-plantar pustular psoriasis	Phase 2	Phase 2 data due 2H 2020.
ANB019	Generalized pustular psoriasis	Phase 2	Phase 2 interim data on first TWO patients announced September 30, 2019 with patients reaching primary endpoint. Further data due 2020.
ANB020 - etokimab	Nasal polyps	Phase 2	Phase 2 data due 1H 2020.

ANCN Anchiano Therapeutics Ltd.

$1.33

-0.02  -1.14%

7.4 million

$9.9 million

2.1 thousand

41.7 thousand

0.05

$1.07

$1.32

$1.35

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
Inodiftagene - Codex	Non-muscle invasive bladder cancer (NMIBC)	Phase 2	Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.
Inodiftagene with BCG - Leo	Non-muscle invasive bladder cancer (NMIBC)	Phase 3	Phase 3 planned for 4Q 2019 or 1Q 2020.

ANIK Anika Therapeutics Inc.

$45.55

+0.34  +0.75%

14.3 million

$650 million

149.9 thousand

165.5 thousand

0.91

$2.31

$45.27

$45.21

01/29/2020

Tap to view 3 drug drugs

Drug	Indication	Stage	News
Cingal	Osteoarthritis	Phase 3	Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated 1H 2020.
Monovisc	Osteoarthritis	Approved	Approved Feb 2014
HYALOFAST	Cartilage defects of the knee	Phase 3	Phase 3 enrollment to be completed by the end of 2018.

ANIX Anixa Biosciences Inc.

$3.77

-0.19  -4.80%

20.8 million

$78.5 million

42.1 thousand

84.6 thousand

0.5

$13.00

$3.80

$3.96

01/29/2020

Tap to view 1 drug drugs

Drug	Indication	Stage	News
Breast cancer vaccine		Phase 1

ANVS Annovis Bio Inc

$8.94

  +0.00%

$

3 million

0

0

$0.00

$6.63

$0.00

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
ANVS401	Alzheimer’s disease	Phase 2a	Phase 2a trial ongoing.
ANVS401	Parkinson’s disease	Phase 2a	Phase 2a trial ongoing.

APLS Apellis Pharmaceuticals Inc.

$42.09

+0.44  +1.06%

74.9 million

$3.2 billion

467.3 thousand

1.6 million

0.29

$19.31

$41.46

$41.65

01/29/2020

Tap to view 7 drug drugs

Drug	Indication	Stage	News
APL-2 subcutaneous	Cold agglutinin disease (CAD)	Phase 2	Phase 3 trial plan update due early 2020.
APL-2 PHAROAH	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 1b	Phase 1b trial ongoing.
APL-2 OAKS	Geographic atrophy (GA) associated with age-related macular degeneration (AMD)	Phase 3	Phase 3 enrolment to be completed 1Q 2020.
APL-2 subcutaneous PEGASUS	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 data met primary endpoint - January 7, 2020.
APL-2 PADDOCK	Paroxysmal Nocturnal Hemoglobinuria	Phase 1	Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 subcutaneous	Complement-dependent Nephropathies (CDN)	Phase 2	Phase 2 initial data presented at ASN November 8, 2019.
APL-2 PRINCE	Paroxysmal Nocturnal Hemoglobinuria (PNH)	Phase 3	Phase 3 commencement of dosing announced September 3, 2019.

APLT Applied Therapeutics Inc.

$50.49

+0.66  +1.32%

18.5 million

$934.8 million

125.1 thousand

209.6 thousand

0.6

$30.42

$49.71

$49.83

01/29/2020

Tap to view 2 drug drugs

Drug	Indication	Stage	News
AT-001	Diabetic cardiomyopathy (DbCM)	Phase 3	Phase 3 trial initiation announced September 4, 2019.
AT-007	Galactosemia	Phase 2	Phase 2 data January 8, 2019 noted significant plasma galactitol reduction of ~50% (p<0.01). Full data to be presented at the Society for Inherited Metabolic Disorders Annual Meeting, April 26 – 29, 2020.

APRE Aprea Therapeutics Inc - Ordinary Shares

$34.14

-1.8  -5.01%

21 million

$716.6 million

25.5 thousand

131 thousand

0.2

-$10.13

$35.76

$35.94

01/29/2020

Tap to view 4 drug drugs

Drug	Indication	Stage	News
APR-246 and azacitidine	Myelodysplastic syndromes (MDS)/Acute myeloid leukemia (AML) Post-Transplant Trial	Phase 2	Phase 2 data due 1H 2021.
APR-246 and azacitidine	Myelodysplastic syndromes (MDS)	Phase 2	Phase 2 data at ASH December 9, 2019. 88% ORR, 61% CR rate.
APR-246 and azacitidine	TP53 mutant Myelodysplastic syndromes (MDS)	Phase 2/3	Phase 3 initial data due 3Q 2020.
APR-246 and azacitidine	TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML)	Phase 2	Phase 2 data presented at ASH December 9, 2019. 74% ORR, 66% CR rate.

APTO Aptose Biosciences Inc.

$6.60

+0.56  +9.27%

76.1 million

$502.3 million

854.6 thousand

1.4 million

0.63

$11.09

$6.12

$6.04

01/29/2020